期刊文献+

食管癌后程加速超分割调强适形放疗及联用尼妥珠单抗的研究 被引量:12

Clinical study on late course accelerated hyperfractionated intensity modulated radiation therapy plus nimotuzumab for esophageal carcinoma
原文传递
导出
摘要 目的 比较食管癌后程加速超分割调强适形放疗和后程加速超分割调强适形放疗联用尼妥珠单抗的疗效与毒性.方法 64例无远处转移的初治、评估认为无法耐受同步放化疗的食管鳞状细胞癌患者随机分组,32例行后程加速超分割调强适形放疗(后超调强组):先行放疗41.4 Gy/23次,共5周,后行放疗27 Gy/18次,共2周;32例行后程加速超分割调强适形联合尼妥珠单抗治疗(联合组):放射治疗方法同后超调强组,在放射治疗的开始时同期均加用6~8周的尼妥珠单抗(200 mg,静脉滴注,1次/周,共6~8周),从放疗第1天起执行.观察指标主要包括食管和肺的近期急性反应和后期放射损伤、过敏等不良反应以及临床受益率、1~3年局控率、无瘤生存率、总体生存率等.结果 后超调强组和联合组患者在放射性食管炎、放射性肺炎、骨髓抑制、消化道反应、皮疹、过敏等不良反应的发生方面差异无统计学意义(P>0.05).晚期并发症主要表现为食管狭窄和肺纤维化,两组比较差异无统计学意义(P>0.05).联合组有1例患者出现过敏性休克后放弃治疗.后超调强组和联合组患者临床受益率分别为75.0%(24/32)、93.7%(30/32),两组差异有统计学意义(P<0.05).联合组总生存率和无瘤生存率均高于后超调强组,但差异无统计学意义(P>0.05).结论 后程加速超分割调强适形放疗联合尼妥珠单抗治疗食管癌临床受益率明显高于后超调强组,但无瘤生存率和总体生存率的差别无统计学意义;后程加速超分割调强适形放疗联合尼妥珠单抗治疗食管癌未明显增加不良反应,部分可能出现过敏反应,应注意预防和加强处理. Objective To compare the treatment result and the toxicity between the late course accelerated hyperfractionated intensity modulated radiation therapy (LCAF) and LCAF plus nimotuzumab for esophageal carcinoma.Methods 64 patients with esophageal squamous cell carcinoma without distance relapse and cannot tolerate the concurrent chemoradiotherapy were randomized into two groups.32 patients in group of LCAF received the first stage of radiation with a dose of 41.4 Gy/23 f/5 weeks,and then received the second stage of radiation with a dose of 27 Gy/18 f/2 weeks.32 patients in group of combination were treated by the same way plus nimotuzumab.The toxicity,the late reaction,the response rate,local control rate,distant-metastasis-free survivalrate and total survivalrate were compared between the two groups.Results The incidence of toxicity including radiation esophagitis,radiation pneumonitis,myelosuppression,gastrointestinal reaction,tetter and allergy showed no significant difference between group LCAF and group combination (P 〉 0.05).The incidence of late complications as esophagostenosis and lung fibrosis have no significance between group LCAF and group combination (P 〉 0.05).One patient in group of combination appeared anaphylactic shock and gave up the treatment.The response rate in group of combination was significant improved compared with group of LCAF (75.0 % vs 93.7 %,P 〈 0.05).The over survival rate and the distant-metastasis-fiee survival rate in group of combination were higher than those in group of LCAF,but showed no statistical significance (P 〉 0.05).Conclusions Most patients of esophageal carcinoma have good tolerance of LCAF plus nimotuzumab.Anaphylactic reaction maybe appear while accepting nimotuzumab which need be mentioned.The over survival rate and the distant-metastasis-free survival rate of LCAF plus nimotuzumab are advantage,but has no statistical significance,LCAF combined with nimotuzmab has a higher clinical benefit.
出处 《肿瘤研究与临床》 CAS 2014年第8期514-517,522,共5页 Cancer Research and Clinic
关键词 食管肿瘤 放疗疗法 尼妥珠单抗 不良反应 预后 Esophageal carcinoma Radiotherapy Nimotuzumab Side effects Prognosis
  • 相关文献

参考文献7

二级参考文献63

  • 1黄晓东,易俊林,高黎,徐国镇,金晶,杨伟志,卢泰祥,吴少雄,吴仁瑞,胡伟汉,谢伟长,韩非,高远红,高剑铭,潘建基,陈传本,朗锦义,李涛,董昱,付玉彬,樊林,李柏森,黎静,王晓怀,陈炳旭,高献书,张萍,吴湘玮,胡炳强.抗表皮生长因子受体单克隆抗体h—R3联合放疗治疗晚期鼻咽癌的Ⅱ期临床研究[J].中华肿瘤杂志,2007,29(3):197-201. 被引量:99
  • 2孙光远,赵学维,李兵,徐志飞,何金,刘惠敏.EGFR在女性非小细胞肺癌中的表达及临床意义[J].中国癌症杂志,2007,17(5):380-384. 被引量:10
  • 3Naravan NA, Yamada J, Berry S, et al. Intensity-modulated radiotherapy in high-grade gliomas: clinical and dosimetric results [ J ]. Int J Radiat Oncol Biol Phys, 2006, 64(3): 892- 897.
  • 4Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy [J]. Cancer, 2002, 94(5): 1593-1611.
  • 5Chakravarti A, Berkey B, Robins HI, et al. An update of phase I / II study of gefitinib with radiotherapy in newly diagnosed glioblastoma[J].J Clin Oncol, 2006, 24(18suppl): 1527.
  • 6Brown PD, Krishnan S, Sarkaria JN, et al. Phase I /II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma muhiforme: North Central Cancer Treatment Group Study N0177 [ J ] . J Clin Oneol, 2008,26(34): 5603-5609.
  • 7Tania CR, Javier F, Mauricio C, et al. Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor(EGFR) antibody h-R3: Report from a phase I /II trial [ J ] . Cancer Biol Ther, 2006, 5(4): 375-379.
  • 8Stephanie E, Combs MN, Lutz E, et al. Comparative evaluation of radiochemotherapy with temozolomide versus standard-of- care postoperative radiation alone in patients with WHO grade Ⅲ astrocytic tumors [ J ] . Radiother Oncol, 2008, 88(2): 177-182.
  • 9Stupp R, Waren P. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma [J].N Engl J Med, 2005, 352(10): 987-996.
  • 10Herrlinger U, Reiger J, Koch D, et al. Phase Ⅱ trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03 [ J ] . J Clin Oncol, 2008, 24(27): 4412-4417.

共引文献283

同被引文献104

引证文献12

二级引证文献82

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部